Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating anakinra to prevent severe CAR-T cell-related encephalopathy in patients with recurrent or refractory diffuse large…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial of epcoritamab in combination with Rituximab-mini CVP for newly diagnosed diffuse large B-cell lymphoma in older unfit/frail o…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial evaluating CC-99282 in combination with Rituximab given early after CAR T therapy in patients with relapsed or refractory B-ce…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL [Phase 2]
A Phase 2 clinical trial examining Surovatamig (AZD0486) as monotherapy in relapsed/refractory B-cell non-Hodgkin lymphoma, including follic…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma [Phase 1]
Phase 1 trial update of ViPOR-P (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in combination with polatuzumab for relapsed…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Outpatient Epcoritamab as 2L in NTE R/R DLBCL [Phase 2]
Outpatient epcoritamab is being studied as second-line therapy for relapsed or refractory diffuse large B-cell lymphoma in a Phase 2 trial, …
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial from City of Hope evaluating CMV-specific CD19-CAR T-cells with CMV-MVA Triplex vaccine after stem cell transplantati…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Long-term Follow up Local Registry Study of Kymriah in South Korea
This clinical trial update reports a long-term follow-up local registry study of Kymriah in South Korea. Recruitment is ongoing for patients…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignanci…
-
FDA approval · 2026-02-20FDA Approved: ZYNLONTA — Supplemental Application (ADC Therapeutics America, Inc.)
FDA overview of a supplemental application for ZYNLONTA (loncastuximab tesirine) by ADC Therapeutics America, Inc., indicating an additional…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab [Phase 1, Phase 2]
BeiGene announced completion and posted results for a Phase 1/2 study of BGB-10188 as monotherapy and in combination with zanubrutinib and t…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) [Phase 2]
A Phase 2 trial of pembrolizumab in PD-L1–expressing Diffuse Large B-Cell Lymphoma was terminated, and results were posted on February 20, 2…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]
Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports ongoing Phase 1/2 testing of the combination epcoritamab plus ibrutinib for relapsed or refractory aggres…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas [Phase 1]
Phase 1 trial evaluating pomalidomide with dose-adjusted EPOCH, with or without rituximab, for HIV-associated lymphomas; recruitment is ongo…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A pharmacokinetic study is evaluating how crushing venetoclax tablets and dissolving them in solution affects drug exposure, to assess alter…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL [Phase 1, Phase 2]
This is an early-phase clinical trial evaluating polatuzumab vedotin in combination with rituximab and chidamide for newly diagnosed elderly…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 study evaluating the safety and efficacy of Glofitamab in combination with Rituximab-CHOP in untreated diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma [EARLY_Phase 1]
This is an early-phase (Phase 1) clinical trial update for Iomab-ACT, which combines 131-I-labeled apamistamab with CD19-targeted CAR T-cell…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R [NA]
A single-arm, non-randomized pilot trial to evaluate the safety of autologous anti-CD19 CAR-T cells (ARI-0001) and the feasibility of local …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial update from Northwestern University evaluating the combination of epcoritamab and lenalidomide in patients with refractory o…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
A real-world study is evaluating subcutaneous epcoritamab in adults with diffuse large B-cell lymphoma and follicular lymphoma and is curren…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies [Phase 1]
Phase 1 pilot study evaluating anti-CD19 CAR-T cells for relapsed/refractory CD19+ malignancies; the trial is currently recruiting at the Un…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…